DBV Technologies (DBVT) Cut to Strong Sell at BidaskClub
DBV Technologies (NASDAQ:DBVT) was downgraded by equities research analysts at BidaskClub from a “sell” rating to a “strong sell” rating in a research report issued on Tuesday.
DBVT has been the topic of several other research reports. Zacks Investment Research raised DBV Technologies from a “hold” rating to a “buy” rating and set a $32.00 price objective on the stock in a report on Tuesday, October 24th. HC Wainwright reissued a “buy” rating and set a $50.00 price objective on shares of DBV Technologies in a report on Monday, October 23rd. JMP Securities started coverage on DBV Technologies in a report on Friday, November 17th. They set an “outperform” rating on the stock. Societe Generale raised DBV Technologies from a “sell” rating to a “hold” rating in a report on Tuesday, October 31st. Finally, Barclays cut their price objective on DBV Technologies from $58.00 to $30.00 and set an “overweight” rating on the stock in a report on Monday, October 23rd. Three equities research analysts have rated the stock with a sell rating, two have given a hold rating and eight have issued a buy rating to the company. The stock has a consensus rating of “Hold” and a consensus target price of $49.63.
Shares of DBV Technologies (DBVT) opened at $26.23 on Tuesday. DBV Technologies has a twelve month low of $20.08 and a twelve month high of $50.57.
TRADEMARK VIOLATION NOTICE: “DBV Technologies (DBVT) Cut to Strong Sell at BidaskClub” was published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this report on another site, it was illegally copied and republished in violation of US and international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2018/02/15/dbv-technologies-dbvt-cut-to-strong-sell-at-bidaskclub.html.
About DBV Technologies
DBV Technologies SA is a France-based clinical-stage biopharmaceutical company focused on changing the field of immunotherapy by developing a technology platform called Vaskin. The Company’s therapeutic approach is based on epicutaneous immunotherapy, or EPIT, its proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin.
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.